NAGOYA/OSAKA: Japan lags behind other Asian nations in the start-up scene, but it has big dreams to change that. It aspires to be home to 100,000 start-ups, including 100 unicorns, by March 2028 ...

NAGOYA/OSAKA – Japan lags behind other Asian nations in the start-up scene, but it has big dreams to change that. It aspires to be home to 100,000 start-ups, including 100 unicorns, by March ...

Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been launched in Japan for the treatment of adult patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

Daiichi Sankyo has made a little bit of pharma industry history, becoming the first drugmaker to win approval in Japan for a therapy for cancer based on a virus that selectively kills malignant cells.

U.S. President Donald Trump has made numerous tariff threats since returning to office on January 20, ranging from a universal duty on imports to targeted tariffs on specific sectors or countries ...

AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), this time for ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Voice actors Akio Ōtsuka, Hiroshi Kamiya, and Kōki Uchiyama talk about their All For One experiences. With the final season of the popular anime series My Hero Academia steadily approaching its ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.